ログイン

HEMATOLOGY PROGRESS EXAM PART 2

HEMATOLOGY PROGRESS EXAM PART 2
100問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    All new laboratory assays and all assay modifications require validation. Validation is an activity comprised of procedures to determine: 1. Accuracy and precision 2. Specificity 3. Limits 4. Linearity * 0/1 1 and 2 1, 2 and 3 1, 2 and 4 1, 2, 3 and 4

    1, 2, 3 and 4

  • 2

    Relatively easy to measure and maintain: * 1/1 Specificity Sensitivity Accuracy Precision

    Precision

  • 3

    Ability to generate results proportional to the calculated concentration or activity of the analyte: * 0/1 Accuracy Precision Delta check Linearity

    Linearity

  • 4

    The positive predictive value predicts the probability that an individual with a positive assay result ____ the disease or condition. * 0/1 Has (have) Could have May have Will have

    Has (have)

  • 5

    The average human possesses ____ liters of blood. * 0/1 3 liters 5 liters 8 liters 10 liters

    5 liters

  • 6

    The tourniquet should be applied _____ inches above the venipuncture site. * 1/1 1 to 2 inches 3 to 4 inches 5 to 6 inches 8 to 10 inches

    3 to 4 inches

  • 7

    A properly tied tourniquet: * 1/1 Ends pointing away from the shoulder Ends pointing towards the shoulder Loop towards the shoulder Tied like a ribbon

    Ends pointing towards the shoulder

  • 8

    Which of the following is the finger of choice for skin puncture? * 1/1 Middle and index finger Middle and ring finger Ring and index finger None of the above

    Middle and ring finger

  • 9

    Heel punctures in infants should not be made more than __ mm deep because of the risk of bone injury and possible infection (osteomyelitis). * 1/1 Not more than 1 mm deep Not more than 2 mm deep Not more than 3 mm deep Not more than 5 mm deep

    Not more than 2 mm deep

  • 10

    Arrange the following: order of draw from venipuncture. 1. Sodium fluoride with or without EDTA or oxalate (gray stopper) 2. Serum tube with or without activator (red, gold, red-gray marbled, orange, or yellow-gray stopper) 3. Heparin tube (green or light green stopper) 4. EDTA tube (lavender or pink stopper) 5. Coagulation tube (light blue stopper) 6. Blood culture tube (yellow stopper) 6-2-5-3-4-1 6-2-5-4-3-1 6-5-2-3-4-1 6-5-3-4-1-2

    6-5-2-3-4-1

  • 11

    CLSI recommends the following order of draw for skin puncture: 1. EDTA microcollection tube 2. Other microcollection tubes with anticoagulants 3. Serum microcollection tube 4. Slides, unless made from a specimen in the EDTA microcollection tube 5. Tube for blood gas analysis * 1/1 4-1-2-3-5 4-3-1-2-5 5-4-3-1-2 5-4-1-2-3

    5-4-1-2-3

  • 12

    Leakage of a large amount of blood around the puncture site causes the area to rapidly swell: * 1/1 Ecchymosis (bruise) Hematoma Hemoconcentration Syncope

    Hematoma

  • 13

    The tetraploid DNA is checked for proper replication and damage; G2 takes approximately 4 hours. 1/1 G1 S G2 M

    G2

  • 14

    Apoptosis: 1. Cell size enlarged due to swelling 2. Cell size reduced due to shrinkage 3. Nucleus condensation and fragmentation 4. Nucleus exhibits random breaks and lysis (karyolysis) * 1/1 1 and 3 1 and 4 2 and 3 2 and 4

    2 and 3

  • 15

    Major site of blood cell production during the second trimester of fetal development: * 1/1 Bone marrow Spleen Liver Yolk sac

    Liver

  • 16

    Adjuvant for infectious disease therapy: 1/1 IL-3 IL-6 IL-12 IL-15

    IL-12

  • 17

    What is the normal distribution of hemoglobinsin healthy adults? * 0/1 80% to 90% Hb A, 5% to 10% Hb A2, 1% to 5% Hb F 80% to 90% Hb A2, 5% to 10% Hb A, 1% to 5% Hb F Greater than 95% Hb A, less than 3.5% Hb A2, 1% to 2% Hb F Greater than 90% Hb A, 5% Hb F, less than 5% Hb A2

    Greater than 95% Hb A, less than 3.5% Hb A2, 1% to 2% Hb F

  • 18

    As a blood cell matures, the ratio of nucleus to cytoplasm (N:C) in most cases: * 1/1 Increases Decreases Remains the same Variable

    Decreases

  • 19

    All of the following are components of basophil secondary granules, EXCEPT: * 1/1 Catalase Chondroitin sulfates (heparan) Histamine Vascular endothelial factors

    Catalase

  • 20

    Least numerous of the WBCs, making up between 0% and 2% of circulating leukocytes and less than 1% of nucleated cells in the bone marrow: * 0/1 Lymphocytes Basophils Eosinophils Neutrophils

    Basophils

  • 21

    Not considered to be leukocyte: * 0/1 B lymphocytes T lymphocytes Monocytes Mast cells

    Mast cells

  • 22

    “Control center” for platelet activation: * 1/1 Dense tubular system Microfilament and microtubules Open canalicular system Plasma membrane

    Dense tubular system

  • 23

    Hormones and cytokines that control megakaryocytopoiesis: 1. TPO 2. IL-3 3. IL-6 4. IL-11 * 1/1 1 and 2 1 and 3 1, 2 and 3 1, 2, 3 and 4

    1, 2, 3 and 4

  • 24

    The megakaryocyte progenitor that undergoes endomitosis is: 1/1 MK-I BFU-Meg CFU-Meg LD-CFU-Meg

    LD-CFU-Meg

  • 25

    Morphologists call the least differentiated megakaryocyte precursor: * 0/1 LD-CFU-Meg MK-I MK-II MK-III

    MK-I

  • 26

    Platelets are released into the bone marrow through shedding from _____ proplatelet processes, a process called thrombocytopoiesis. * 1/1 Megakaryoblast Promegakaryocyte Megakaryocyte Any of these

    Megakaryocyte

  • 27

    Upon stimulation, platelets change in shape from discoid to _____, extend pseudopods, undergo internal contraction resulting in centralization of their alpha granules and dense granules, and release the granule contents. * 0/1 Cylindrical Irregular Oval Spherical

    Spherical

  • 28

    Potentially prothrombotic, and may be associated with increased risk of cardiovascular disease: * 0/1 Resting platelets Circulating resting platelets Reticulated platelets All of these

    Reticulated platelets

  • 29

    Functions of platelet cytoskeleton: 1. Providing the structure for maintaining the circulating discoid shape of the cell 2. Maintains the position of the organelles 3. Mediate the membrane contact reactions * 0/1 1 only 1 and 2 1 and 3 1, 2 and 3

    1 and 2

  • 30

    Part of the platelet that mediates the membrane contact reactions of platelet adherence, change of cellular shape, internal contraction, and aggregation: * 1/1 Glycocalyx Cytoplasmic membrane Microfilaments and microtubules Granules

    Glycocalyx

  • 31

    For manual WBC count: after charging the hemacytometer, place it in a moist chamber for ___ minutes before counting the cells to give them time to settle. * 1/1 3 minutes 5 minutes 10 minutes 15 minutes

    10 minutes

  • 32

    For manual platelet count, place the charged hemacytometer in a moist chamber for ___ minutes to allow the platelets to settle. * 1/1 3 minutes 5 minutes 10 minutes 15 minutes

    15 minutes

  • 33

    If fewer than 50 platelets are counted on each side, the procedure should be repeated by diluting the blood to: * 1/1 1:10 1:20 1:100 1:200

    1:20

  • 34

    If more than 500 platelets are counted on each side, a ____ dilution should be made. 0/1 1:10 1:20 1:100 1:200

    1:200

  • 35

    Full conversion of hemoglobin to cyanmethemoglobin: 1/1 3 minutes 5 minutes 10 minutes 15 minutes

    10 minutes

  • 36

    WBC and platelet count that can interfere with the cyanmethemoglobin method: * 0/1 High WBC count > 20 x 10^9/L or high platelet count > 400 x 10^9/L High WBC count > 20 x 10^9/L or high platelet count > 700 x 10^9/L High WBC count > 70 x 10^9/L or high platelet count > 200 x 10^9/L High WBC count > 70 x 10^9/L or high platelet count > 400 x 10^9/L

    High WBC count > 20 x 10^9/L or high platelet count > 700 x 10^9/L

  • 37

    In the cyanmethemoglobin method, lipemia can cause turbidity and a falsely high result. It can be corrected by adding ____ mL of the patient’s plasma to ___ mL of the cyanmethemoglobin reagent and using this solution as the patient blank. * 0/1 1 mL patient’s plasma and 5 mL cyanmethemoglobin reagent 1 mL patient’s plasma and 10 mL cyanmethemoglobin reagent 0.01 mL patient’s plasma and 5 mL cyanmethemoglobin reagent 0.02 mL Patient’s plasma and 5 mL cyanmethemoglobin reagent

    0.01 mL patient’s plasma and 5 mL cyanmethemoglobin reagent

  • 38

    The values of the duplicate hematocrits should agree within: * 0/1 1% 5% 10% 20%

    1%

  • 39

    When the microhematocrit centrifuge is calibrated, one of the samples used must have a hematocrit of: 0/1 30% or higher 40% or higher 45% or higher 50% or higher

    50% or higher

  • 40

    Effect of short draw to hematocrit reading: * 0/1 Decreased Increased Variable Cannot be determined

    Decreased

  • 41

    Effect of dehydration to hematocrit reading: * 0/1 Decreased Increased Variable Cannot be determined

    Increased

  • 42

    An MCHC between 36 and 38 g/dL should be checked for: * 0/1 Hypochromic RBCs Macrocytic RBCs Microcytic RBCs Spherocytes

    Spherocytes

  • 43

    Duplicate reticulocyte counts should agree within: * 1/1 1% 5% 10% 20%

    20%

  • 44

    Effect of short draw to ESR determination: * 0/1 Decreased Increased Variable Cannot be determined

    Decreased

  • 45

    Increased ESR: 1. Anemia 2. Macrocytosis 3. Sickle cells 4. Spherocytes * 0/1 1 and 2 1 and 3 1, 2 and 3 1, 2, 3 and 4

    1 and 2

  • 46

    Effects of cold agglutinins to automated cell count: * 1/1 Decreased RBCs, MCV and MCHC Increased RBCs, MCV and MCHC Increased RBCs; decreased MCV and MCHC Decreased RBCs; increased MCV and MCHC

    Decreased RBCs; increased MCV and MCHC

  • 47

    Effects of microcytes and schistocytes to automated cell count: * 1/1 Decreased RBCs and platelets Increased RBCs and platelets Increased RBCs and decreased platelets Decreased RBCs and increased platelets

    Decreased RBCs and increased platelets

  • 48

    Large platelet clumps are counted as ____ and not platelets. * 1/1 RBCs Retics WBCs Any of these

    WBCs

  • 49

    Which of the following can be used with the MCV for initial classification of anemia? * 0/1 RBC count RDW MPV PDW

    RDW

  • 50

    Which of the following can provide an early indication of engraftment success after hematopoietic stem cell transplant? 1. RBC count 2. Immature reticulocyte fraction 3. Immature platelet fraction * 0/1 1 and 2 1 and 3 2 and 3

    2 and 3

  • 51

    May be useful in distinguishing thrombocytopenia due to idiopathic thrombocytopenia purpura (high value), inherited macrothrombocytopenia (higher value), or bone marrow suppression (low value): * 1/1 RBC count Platelet count MCV MPV

    MPV

  • 52

    Uses detection of interference in a laser beam or light source to differentiate and enumerate cell types: * 0/1 Electronic impedance LASER technology Optical scatter Radiofrequency

    Optical scatter

  • 53

    Capstone of a panel of tests called the complete blood count (CBC) or hemogram: * 1/1 WBC count Hematocrit determination Hemoglobin determination Peripheral film evaluation

    Peripheral film evaluation

  • 54

    Counterproductive smear drying technique because the moisture causes RBCs to become echinocytic (crenated) or to develop water artifact (also called drying artifact): * 0/1 Natural drying Use of small fan Blowing of breath None of these

    Blowing of breath

  • 55

    Wright stain or a Wright-Giemsa stain (Romanowsky stain) is used for staining peripheral blood films and bone marrow smears. These are considered polychrome stains because they contain: * 0/1 Hematoxylin and eosin Hematoxylin and methylene blue Methylene blue and eosin Crystal violet and safranin

    Hematoxylin and eosin

  • 56

    The Clinical and Laboratory Standards Institute (CLSI) recommends that bands and neutrophils be counted: * 1/1 Separately and placed in two categories Together and placed in a single category Either of these Neither of these

    Together and placed in a single category

  • 57

    Detects lymphocytic cells and certain abnormal erythrocytic cells by staining of cytoplasmic glycogen: * 1/1 MPO SBB PAS TRAP

    PAS

  • 58

    Anemia is due to the infiltration of abnormal cells into the bone marrow and subsequent destruction and replacement of normal hematopoietic cells: * 1/1 Aplastic anemia Pure red cell aplasia Myelophthisic anemia Anemia of chronic kidney disease

    Myelophthisic anemia

  • 59

    In the Plasmodium life cycle, merozoite becomes a ring form, which grows into a mature trophozoite, then into an immature schizont (chromatin dividing), and finally into a mature schizont that contains merozoites. The phase described occurs in: * 0/1 Anopheles mosquito, intermediate host Anopheles mosquito, definitive host Man, intermediate host Man, definitive host

    Man, intermediate host

  • 60

    Deletion of three alpha globin genes: * 1/1 Silent carrier state Alpha thalassemia minor Hemoglobin H disease Bart’s hydrops fetalis

    Hemoglobin H disease

  • 61

    Primarily a disease of childhood and adolescence, accounting for 25% of childhood cancers and up to 75% of childhood leukemia: * 1/1 ALL AML CLL CML

    ALL

  • 62

    Deficiencies of platelet dense granules: 1. Hermansky-Pudlak syndrome 2. Chédiak-Higashi syndrome 3. Wiskott-Aldrich syndrome 4. Gray platelet syndrome 0/1 1 and 2 1 and 3 1, 2 and 3 1, 2, 3 and 4

    1, 2 and 3

  • 63

    Disorders of platelet aggregation, EXCEPT: * 0/1 Acquired uremia Bernard-Soulier syndrome Glanzmann’s thrombasthenia Hereditary afibrinogenemia

    Bernard-Soulier syndrome

  • 64

    The ratio of whole blood to anticoagulant for coagulation studies must be: * 1/1 1:4 1:9 4:1 9:1

    9:1

  • 65

    Blood collection volume less than specified minimum: * 1/1 PT falsely shortened; recollect specimen PT falsely prolonged; recollect specimen Variable Cannot be determined

    PT falsely prolonged; recollect specimen

  • 66

    Sensitive early marker for liver disease: * 1/1 Platelet count PT PTT Thrombin time

    PT

  • 67

    Assesses deficiencies of all factors except VII and XIII: * 1/1 Platelet count PT PTT TT

    PTT

  • 68

    Uncontrolled activation of thrombin and consumption of coagulation factors, platelets, and fibrinolytic proteins secondary to many initiating events, including infection, inflammation, shock, and trauma. Most commonly evidenced by diffuse mucocutaneous bleeding. * 0/1 Disseminated intravascular coagulation Rosenthal syndrome von Willebrand’s disease Wiskott-Aldrich syndome

    Disseminated intravascular coagulation

  • 69

    Which of the following is the preferable site for bone marrow aspiration and biopsy in an adult? * 1/1 liac crest Sternum Tibia Spinous processes of a vertebra

    liac crest

  • 70

    What effect would using a buffer at pH 6.0 have on a Wright’s-stained smear? * 1/1 Red cells would be stained too pink White cell cytoplasm would be stained too blue Red cells would be stained too blue Red cells would lyse on the slide

    Red cells would be stained too pink

  • 71

    What staining method is used most frequently to stain and manually count reticulocytes? * 0/1 Immunofluorescence Supravital staining Romanowsky staining Cytochemical staining

    Supravital staining

  • 72

    The Coulter principle for counting of cells is based upon the fact that: * 1/1 Isotonic solutions conduct electricity better than cells do Conductivity varies proportionally to the number of cells Cells conduct electricity better than saline does Isotonic solutions cannot conduct electricity

    Isotonic solutions conduct electricity better than cells do

  • 73

    Which of the following statistical terms reflects the best index of precision when comparing two CBC parameters? * 1/1 Mean Median Coefficient of variation Standard deviation

    Coefficient of variation

  • 74

    Which of the following is considered a normal hemoglobin? * 0/1 Carboxyhemoglobin Methemoglobin Sulfhemoglobin Deoxyhemoglobin

    Deoxyhemoglobin

  • 75

    Which condition will shift the oxyhemoglobin dissociation curve to the right? * 1/1 Acidosis Alkalosis Multiple blood transfusions Increased quantities of hemoglobin S or C

    Acidosis

  • 76

    Which of the following can shift the hemoglobin oxygen dissociation curve to the right? * 1/1 Increases in 2,3 DPG Acidosis Hypoxia All of these options

    All of these options

  • 77

    Which of the following hemoglobins migrates to the same position as Hgb A2 at pH 8.6? 1/1 Hgb H Hgb F Hgb C Hgb S

    Hgb C

  • 78

    Which is the first stage of erythrocytic maturation in which the cytoplasm is pink due to the formation of hemoglobin? * 1/1 Reticulocyte Pronormoblast Basophilic normoblast Polychromatic normoblast

    Polychromatic normoblast

  • 79

    Which of the following is contained in the primary granules of the neutrophil? * 1/1 Lactoferrin Myeloperoxidase Histamine Alkaline phosphatase

    Myeloperoxidase

  • 80

    The morphological characteristic(s) associated with the Chédiak–Higashi syndrome is (are): * 1/1 Pale blue cytoplasmic inclusions Giant lysosomal granules Small, dark-staining granules and condensed nuclei Nuclear hyposegmentation

    Giant lysosomal granules

  • 81

    Lazy leukocyte syndrome: * 0/1 Monocyte-macrophage series Neutrophilic series Lymphocytic series Erythrocytic series

    Neutrophilic series

  • 82

    Disseminated intravascular coagulation (DIC) is most often associated with which of the following types of acute leukemia? * 1/1 Acute myeloid leukemia without maturation Acute promyelocytic leukemia Acute myelomonocytic leukemia Acute monocytic leukemia

    Acute promyelocytic leukemia

  • 83

    CML is distinguished from leukemoid reaction by which of the following? * 1/1 CML: low LAP; leukemoid: high LAP CML: high LAP; leukemoid: low LAP CML: high WBC; leukemoid: normal WBC CML: high WBC; leukemoid: higher WBC

    CML: low LAP; leukemoid: high LAP

  • 84

    What reagents are used in the PT test? * 0/1 Thromboplastin and sodium chloride Thromboplastin and potassium chloride Thromboplastin and calcium Actin and calcium chloride

    Thromboplastin and calcium

  • 85

    Which clotting factor is not measured by PT and APTT tests? * 1/1 Factor VIII Factor IX Factor V Factor XIII

    Factor XIII

  • 86

    A protein that plays a role in both coagulation and platelet aggregation is: * 1/1 Factor I Factor VIII Factor IX Factor XI

    Factor I

  • 87

    Aspirin prevents platelet aggregation by inhibiting the action of which enzyme? * 1/1 Phospholipase Cyclo-oxygenase Thromboxane A2 synthetase Prostacyclin synthetase

    Cyclo-oxygenase

  • 88

    Which of the following prevents platelet aggregation? * 0/1 Thromboxane A2 Thromboxane B2 Prostacyclin Antithrombin

    Prostacyclin

  • 89

    Which test result would be normal in a patient with dysfibrinogenemia? * 1/1 Thrombin time APTT PT Immunologic fibrinogen level

    Immunologic fibrinogen level

  • 90

    Factor XII deficiency is associated with: * 0/1 Bleeding episodes Epistaxis Decreased risk of thrombosis Increased risk of thrombosis

    Increased risk of thrombosis

  • 91

    The most common subtype of classic von Willebrand’s disease is: * 0/1 Type 1 Type 2A Type 2B Type 3

    Type 1

  • 92

    Thrombin-thrombomodulin complex is necessary for activation of: * 1/1 Protein C Antithrombin Protein S Factors V and VIII

    Protein C

  • 93

    What clotting factors (cofactors) are inhibited by protein S? * 1/1 V and X Va and VIIIa VIII and IX VIII and X

    Va and VIIIa

  • 94

    Heparin-induced thrombocytopenia (HIT) results from: * 1/1 Antibodies to heparin Antibodies to platelets Antibodies to PF4 Antibodies to heparin-PF4 complex

    Antibodies to heparin-PF4 complex

  • 95

    In the Clauss fibrinogen assay the time for clot formation in plasma is measured after the addition of: * 1/1 Calcium Thrombin Phospholipids Fibrin

    Thrombin

  • 96

    A pregnant women has routine coagulation testing performed. PT and aPTT are normal. Her fibrinogen level is elevated at 450 (reference range 150-350) due to acute phase reactants during pregnancy. The other factor that may be elevated due to this is: * 0/1 FVII FVIII FXI FXIII

    FVIII

  • 97

    Platelet aggregation will occur with the end production of: * 1/1 Cyclooxygenase Arachidonic acid Prostacyclin Thromboxane A2

    Thromboxane A2

  • 98

    After the removal of red blood cells from the circulation hemoglobin is broken down into: * 1/1 Iron, porphyrin, and amino acids Iron, heme, and globin Heme, protoporphyrin, and amino acids Heme, hemosiderin, and globin

    Iron, heme, and globin

  • 99

    Deficiency of this enzyme is associated with a moderate to severe hemolytic anemia after the patient is exposed to certain drugs and characterized by red cell inclusions formed by denatured hemoglobin: * 1/1 Lactate dehydrogenase G6PD Pyruvate kinase Hexokinase

    G6PD

  • 100

    What protein is commonly defective in hereditary elliptocytosis? [BOC] * 1/1 Ankyrin Spectrin Band 4.1 Elliptocin

    Spectrin

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    All new laboratory assays and all assay modifications require validation. Validation is an activity comprised of procedures to determine: 1. Accuracy and precision 2. Specificity 3. Limits 4. Linearity * 0/1 1 and 2 1, 2 and 3 1, 2 and 4 1, 2, 3 and 4

    1, 2, 3 and 4

  • 2

    Relatively easy to measure and maintain: * 1/1 Specificity Sensitivity Accuracy Precision

    Precision

  • 3

    Ability to generate results proportional to the calculated concentration or activity of the analyte: * 0/1 Accuracy Precision Delta check Linearity

    Linearity

  • 4

    The positive predictive value predicts the probability that an individual with a positive assay result ____ the disease or condition. * 0/1 Has (have) Could have May have Will have

    Has (have)

  • 5

    The average human possesses ____ liters of blood. * 0/1 3 liters 5 liters 8 liters 10 liters

    5 liters

  • 6

    The tourniquet should be applied _____ inches above the venipuncture site. * 1/1 1 to 2 inches 3 to 4 inches 5 to 6 inches 8 to 10 inches

    3 to 4 inches

  • 7

    A properly tied tourniquet: * 1/1 Ends pointing away from the shoulder Ends pointing towards the shoulder Loop towards the shoulder Tied like a ribbon

    Ends pointing towards the shoulder

  • 8

    Which of the following is the finger of choice for skin puncture? * 1/1 Middle and index finger Middle and ring finger Ring and index finger None of the above

    Middle and ring finger

  • 9

    Heel punctures in infants should not be made more than __ mm deep because of the risk of bone injury and possible infection (osteomyelitis). * 1/1 Not more than 1 mm deep Not more than 2 mm deep Not more than 3 mm deep Not more than 5 mm deep

    Not more than 2 mm deep

  • 10

    Arrange the following: order of draw from venipuncture. 1. Sodium fluoride with or without EDTA or oxalate (gray stopper) 2. Serum tube with or without activator (red, gold, red-gray marbled, orange, or yellow-gray stopper) 3. Heparin tube (green or light green stopper) 4. EDTA tube (lavender or pink stopper) 5. Coagulation tube (light blue stopper) 6. Blood culture tube (yellow stopper) 6-2-5-3-4-1 6-2-5-4-3-1 6-5-2-3-4-1 6-5-3-4-1-2

    6-5-2-3-4-1

  • 11

    CLSI recommends the following order of draw for skin puncture: 1. EDTA microcollection tube 2. Other microcollection tubes with anticoagulants 3. Serum microcollection tube 4. Slides, unless made from a specimen in the EDTA microcollection tube 5. Tube for blood gas analysis * 1/1 4-1-2-3-5 4-3-1-2-5 5-4-3-1-2 5-4-1-2-3

    5-4-1-2-3

  • 12

    Leakage of a large amount of blood around the puncture site causes the area to rapidly swell: * 1/1 Ecchymosis (bruise) Hematoma Hemoconcentration Syncope

    Hematoma

  • 13

    The tetraploid DNA is checked for proper replication and damage; G2 takes approximately 4 hours. 1/1 G1 S G2 M

    G2

  • 14

    Apoptosis: 1. Cell size enlarged due to swelling 2. Cell size reduced due to shrinkage 3. Nucleus condensation and fragmentation 4. Nucleus exhibits random breaks and lysis (karyolysis) * 1/1 1 and 3 1 and 4 2 and 3 2 and 4

    2 and 3

  • 15

    Major site of blood cell production during the second trimester of fetal development: * 1/1 Bone marrow Spleen Liver Yolk sac

    Liver

  • 16

    Adjuvant for infectious disease therapy: 1/1 IL-3 IL-6 IL-12 IL-15

    IL-12

  • 17

    What is the normal distribution of hemoglobinsin healthy adults? * 0/1 80% to 90% Hb A, 5% to 10% Hb A2, 1% to 5% Hb F 80% to 90% Hb A2, 5% to 10% Hb A, 1% to 5% Hb F Greater than 95% Hb A, less than 3.5% Hb A2, 1% to 2% Hb F Greater than 90% Hb A, 5% Hb F, less than 5% Hb A2

    Greater than 95% Hb A, less than 3.5% Hb A2, 1% to 2% Hb F

  • 18

    As a blood cell matures, the ratio of nucleus to cytoplasm (N:C) in most cases: * 1/1 Increases Decreases Remains the same Variable

    Decreases

  • 19

    All of the following are components of basophil secondary granules, EXCEPT: * 1/1 Catalase Chondroitin sulfates (heparan) Histamine Vascular endothelial factors

    Catalase

  • 20

    Least numerous of the WBCs, making up between 0% and 2% of circulating leukocytes and less than 1% of nucleated cells in the bone marrow: * 0/1 Lymphocytes Basophils Eosinophils Neutrophils

    Basophils

  • 21

    Not considered to be leukocyte: * 0/1 B lymphocytes T lymphocytes Monocytes Mast cells

    Mast cells

  • 22

    “Control center” for platelet activation: * 1/1 Dense tubular system Microfilament and microtubules Open canalicular system Plasma membrane

    Dense tubular system

  • 23

    Hormones and cytokines that control megakaryocytopoiesis: 1. TPO 2. IL-3 3. IL-6 4. IL-11 * 1/1 1 and 2 1 and 3 1, 2 and 3 1, 2, 3 and 4

    1, 2, 3 and 4

  • 24

    The megakaryocyte progenitor that undergoes endomitosis is: 1/1 MK-I BFU-Meg CFU-Meg LD-CFU-Meg

    LD-CFU-Meg

  • 25

    Morphologists call the least differentiated megakaryocyte precursor: * 0/1 LD-CFU-Meg MK-I MK-II MK-III

    MK-I

  • 26

    Platelets are released into the bone marrow through shedding from _____ proplatelet processes, a process called thrombocytopoiesis. * 1/1 Megakaryoblast Promegakaryocyte Megakaryocyte Any of these

    Megakaryocyte

  • 27

    Upon stimulation, platelets change in shape from discoid to _____, extend pseudopods, undergo internal contraction resulting in centralization of their alpha granules and dense granules, and release the granule contents. * 0/1 Cylindrical Irregular Oval Spherical

    Spherical

  • 28

    Potentially prothrombotic, and may be associated with increased risk of cardiovascular disease: * 0/1 Resting platelets Circulating resting platelets Reticulated platelets All of these

    Reticulated platelets

  • 29

    Functions of platelet cytoskeleton: 1. Providing the structure for maintaining the circulating discoid shape of the cell 2. Maintains the position of the organelles 3. Mediate the membrane contact reactions * 0/1 1 only 1 and 2 1 and 3 1, 2 and 3

    1 and 2

  • 30

    Part of the platelet that mediates the membrane contact reactions of platelet adherence, change of cellular shape, internal contraction, and aggregation: * 1/1 Glycocalyx Cytoplasmic membrane Microfilaments and microtubules Granules

    Glycocalyx

  • 31

    For manual WBC count: after charging the hemacytometer, place it in a moist chamber for ___ minutes before counting the cells to give them time to settle. * 1/1 3 minutes 5 minutes 10 minutes 15 minutes

    10 minutes

  • 32

    For manual platelet count, place the charged hemacytometer in a moist chamber for ___ minutes to allow the platelets to settle. * 1/1 3 minutes 5 minutes 10 minutes 15 minutes

    15 minutes

  • 33

    If fewer than 50 platelets are counted on each side, the procedure should be repeated by diluting the blood to: * 1/1 1:10 1:20 1:100 1:200

    1:20

  • 34

    If more than 500 platelets are counted on each side, a ____ dilution should be made. 0/1 1:10 1:20 1:100 1:200

    1:200

  • 35

    Full conversion of hemoglobin to cyanmethemoglobin: 1/1 3 minutes 5 minutes 10 minutes 15 minutes

    10 minutes

  • 36

    WBC and platelet count that can interfere with the cyanmethemoglobin method: * 0/1 High WBC count > 20 x 10^9/L or high platelet count > 400 x 10^9/L High WBC count > 20 x 10^9/L or high platelet count > 700 x 10^9/L High WBC count > 70 x 10^9/L or high platelet count > 200 x 10^9/L High WBC count > 70 x 10^9/L or high platelet count > 400 x 10^9/L

    High WBC count > 20 x 10^9/L or high platelet count > 700 x 10^9/L

  • 37

    In the cyanmethemoglobin method, lipemia can cause turbidity and a falsely high result. It can be corrected by adding ____ mL of the patient’s plasma to ___ mL of the cyanmethemoglobin reagent and using this solution as the patient blank. * 0/1 1 mL patient’s plasma and 5 mL cyanmethemoglobin reagent 1 mL patient’s plasma and 10 mL cyanmethemoglobin reagent 0.01 mL patient’s plasma and 5 mL cyanmethemoglobin reagent 0.02 mL Patient’s plasma and 5 mL cyanmethemoglobin reagent

    0.01 mL patient’s plasma and 5 mL cyanmethemoglobin reagent

  • 38

    The values of the duplicate hematocrits should agree within: * 0/1 1% 5% 10% 20%

    1%

  • 39

    When the microhematocrit centrifuge is calibrated, one of the samples used must have a hematocrit of: 0/1 30% or higher 40% or higher 45% or higher 50% or higher

    50% or higher

  • 40

    Effect of short draw to hematocrit reading: * 0/1 Decreased Increased Variable Cannot be determined

    Decreased

  • 41

    Effect of dehydration to hematocrit reading: * 0/1 Decreased Increased Variable Cannot be determined

    Increased

  • 42

    An MCHC between 36 and 38 g/dL should be checked for: * 0/1 Hypochromic RBCs Macrocytic RBCs Microcytic RBCs Spherocytes

    Spherocytes

  • 43

    Duplicate reticulocyte counts should agree within: * 1/1 1% 5% 10% 20%

    20%

  • 44

    Effect of short draw to ESR determination: * 0/1 Decreased Increased Variable Cannot be determined

    Decreased

  • 45

    Increased ESR: 1. Anemia 2. Macrocytosis 3. Sickle cells 4. Spherocytes * 0/1 1 and 2 1 and 3 1, 2 and 3 1, 2, 3 and 4

    1 and 2

  • 46

    Effects of cold agglutinins to automated cell count: * 1/1 Decreased RBCs, MCV and MCHC Increased RBCs, MCV and MCHC Increased RBCs; decreased MCV and MCHC Decreased RBCs; increased MCV and MCHC

    Decreased RBCs; increased MCV and MCHC

  • 47

    Effects of microcytes and schistocytes to automated cell count: * 1/1 Decreased RBCs and platelets Increased RBCs and platelets Increased RBCs and decreased platelets Decreased RBCs and increased platelets

    Decreased RBCs and increased platelets

  • 48

    Large platelet clumps are counted as ____ and not platelets. * 1/1 RBCs Retics WBCs Any of these

    WBCs

  • 49

    Which of the following can be used with the MCV for initial classification of anemia? * 0/1 RBC count RDW MPV PDW

    RDW

  • 50

    Which of the following can provide an early indication of engraftment success after hematopoietic stem cell transplant? 1. RBC count 2. Immature reticulocyte fraction 3. Immature platelet fraction * 0/1 1 and 2 1 and 3 2 and 3

    2 and 3

  • 51

    May be useful in distinguishing thrombocytopenia due to idiopathic thrombocytopenia purpura (high value), inherited macrothrombocytopenia (higher value), or bone marrow suppression (low value): * 1/1 RBC count Platelet count MCV MPV

    MPV

  • 52

    Uses detection of interference in a laser beam or light source to differentiate and enumerate cell types: * 0/1 Electronic impedance LASER technology Optical scatter Radiofrequency

    Optical scatter

  • 53

    Capstone of a panel of tests called the complete blood count (CBC) or hemogram: * 1/1 WBC count Hematocrit determination Hemoglobin determination Peripheral film evaluation

    Peripheral film evaluation

  • 54

    Counterproductive smear drying technique because the moisture causes RBCs to become echinocytic (crenated) or to develop water artifact (also called drying artifact): * 0/1 Natural drying Use of small fan Blowing of breath None of these

    Blowing of breath

  • 55

    Wright stain or a Wright-Giemsa stain (Romanowsky stain) is used for staining peripheral blood films and bone marrow smears. These are considered polychrome stains because they contain: * 0/1 Hematoxylin and eosin Hematoxylin and methylene blue Methylene blue and eosin Crystal violet and safranin

    Hematoxylin and eosin

  • 56

    The Clinical and Laboratory Standards Institute (CLSI) recommends that bands and neutrophils be counted: * 1/1 Separately and placed in two categories Together and placed in a single category Either of these Neither of these

    Together and placed in a single category

  • 57

    Detects lymphocytic cells and certain abnormal erythrocytic cells by staining of cytoplasmic glycogen: * 1/1 MPO SBB PAS TRAP

    PAS

  • 58

    Anemia is due to the infiltration of abnormal cells into the bone marrow and subsequent destruction and replacement of normal hematopoietic cells: * 1/1 Aplastic anemia Pure red cell aplasia Myelophthisic anemia Anemia of chronic kidney disease

    Myelophthisic anemia

  • 59

    In the Plasmodium life cycle, merozoite becomes a ring form, which grows into a mature trophozoite, then into an immature schizont (chromatin dividing), and finally into a mature schizont that contains merozoites. The phase described occurs in: * 0/1 Anopheles mosquito, intermediate host Anopheles mosquito, definitive host Man, intermediate host Man, definitive host

    Man, intermediate host

  • 60

    Deletion of three alpha globin genes: * 1/1 Silent carrier state Alpha thalassemia minor Hemoglobin H disease Bart’s hydrops fetalis

    Hemoglobin H disease

  • 61

    Primarily a disease of childhood and adolescence, accounting for 25% of childhood cancers and up to 75% of childhood leukemia: * 1/1 ALL AML CLL CML

    ALL

  • 62

    Deficiencies of platelet dense granules: 1. Hermansky-Pudlak syndrome 2. Chédiak-Higashi syndrome 3. Wiskott-Aldrich syndrome 4. Gray platelet syndrome 0/1 1 and 2 1 and 3 1, 2 and 3 1, 2, 3 and 4

    1, 2 and 3

  • 63

    Disorders of platelet aggregation, EXCEPT: * 0/1 Acquired uremia Bernard-Soulier syndrome Glanzmann’s thrombasthenia Hereditary afibrinogenemia

    Bernard-Soulier syndrome

  • 64

    The ratio of whole blood to anticoagulant for coagulation studies must be: * 1/1 1:4 1:9 4:1 9:1

    9:1

  • 65

    Blood collection volume less than specified minimum: * 1/1 PT falsely shortened; recollect specimen PT falsely prolonged; recollect specimen Variable Cannot be determined

    PT falsely prolonged; recollect specimen

  • 66

    Sensitive early marker for liver disease: * 1/1 Platelet count PT PTT Thrombin time

    PT

  • 67

    Assesses deficiencies of all factors except VII and XIII: * 1/1 Platelet count PT PTT TT

    PTT

  • 68

    Uncontrolled activation of thrombin and consumption of coagulation factors, platelets, and fibrinolytic proteins secondary to many initiating events, including infection, inflammation, shock, and trauma. Most commonly evidenced by diffuse mucocutaneous bleeding. * 0/1 Disseminated intravascular coagulation Rosenthal syndrome von Willebrand’s disease Wiskott-Aldrich syndome

    Disseminated intravascular coagulation

  • 69

    Which of the following is the preferable site for bone marrow aspiration and biopsy in an adult? * 1/1 liac crest Sternum Tibia Spinous processes of a vertebra

    liac crest

  • 70

    What effect would using a buffer at pH 6.0 have on a Wright’s-stained smear? * 1/1 Red cells would be stained too pink White cell cytoplasm would be stained too blue Red cells would be stained too blue Red cells would lyse on the slide

    Red cells would be stained too pink

  • 71

    What staining method is used most frequently to stain and manually count reticulocytes? * 0/1 Immunofluorescence Supravital staining Romanowsky staining Cytochemical staining

    Supravital staining

  • 72

    The Coulter principle for counting of cells is based upon the fact that: * 1/1 Isotonic solutions conduct electricity better than cells do Conductivity varies proportionally to the number of cells Cells conduct electricity better than saline does Isotonic solutions cannot conduct electricity

    Isotonic solutions conduct electricity better than cells do

  • 73

    Which of the following statistical terms reflects the best index of precision when comparing two CBC parameters? * 1/1 Mean Median Coefficient of variation Standard deviation

    Coefficient of variation

  • 74

    Which of the following is considered a normal hemoglobin? * 0/1 Carboxyhemoglobin Methemoglobin Sulfhemoglobin Deoxyhemoglobin

    Deoxyhemoglobin

  • 75

    Which condition will shift the oxyhemoglobin dissociation curve to the right? * 1/1 Acidosis Alkalosis Multiple blood transfusions Increased quantities of hemoglobin S or C

    Acidosis

  • 76

    Which of the following can shift the hemoglobin oxygen dissociation curve to the right? * 1/1 Increases in 2,3 DPG Acidosis Hypoxia All of these options

    All of these options

  • 77

    Which of the following hemoglobins migrates to the same position as Hgb A2 at pH 8.6? 1/1 Hgb H Hgb F Hgb C Hgb S

    Hgb C

  • 78

    Which is the first stage of erythrocytic maturation in which the cytoplasm is pink due to the formation of hemoglobin? * 1/1 Reticulocyte Pronormoblast Basophilic normoblast Polychromatic normoblast

    Polychromatic normoblast

  • 79

    Which of the following is contained in the primary granules of the neutrophil? * 1/1 Lactoferrin Myeloperoxidase Histamine Alkaline phosphatase

    Myeloperoxidase

  • 80

    The morphological characteristic(s) associated with the Chédiak–Higashi syndrome is (are): * 1/1 Pale blue cytoplasmic inclusions Giant lysosomal granules Small, dark-staining granules and condensed nuclei Nuclear hyposegmentation

    Giant lysosomal granules

  • 81

    Lazy leukocyte syndrome: * 0/1 Monocyte-macrophage series Neutrophilic series Lymphocytic series Erythrocytic series

    Neutrophilic series

  • 82

    Disseminated intravascular coagulation (DIC) is most often associated with which of the following types of acute leukemia? * 1/1 Acute myeloid leukemia without maturation Acute promyelocytic leukemia Acute myelomonocytic leukemia Acute monocytic leukemia

    Acute promyelocytic leukemia

  • 83

    CML is distinguished from leukemoid reaction by which of the following? * 1/1 CML: low LAP; leukemoid: high LAP CML: high LAP; leukemoid: low LAP CML: high WBC; leukemoid: normal WBC CML: high WBC; leukemoid: higher WBC

    CML: low LAP; leukemoid: high LAP

  • 84

    What reagents are used in the PT test? * 0/1 Thromboplastin and sodium chloride Thromboplastin and potassium chloride Thromboplastin and calcium Actin and calcium chloride

    Thromboplastin and calcium

  • 85

    Which clotting factor is not measured by PT and APTT tests? * 1/1 Factor VIII Factor IX Factor V Factor XIII

    Factor XIII

  • 86

    A protein that plays a role in both coagulation and platelet aggregation is: * 1/1 Factor I Factor VIII Factor IX Factor XI

    Factor I

  • 87

    Aspirin prevents platelet aggregation by inhibiting the action of which enzyme? * 1/1 Phospholipase Cyclo-oxygenase Thromboxane A2 synthetase Prostacyclin synthetase

    Cyclo-oxygenase

  • 88

    Which of the following prevents platelet aggregation? * 0/1 Thromboxane A2 Thromboxane B2 Prostacyclin Antithrombin

    Prostacyclin

  • 89

    Which test result would be normal in a patient with dysfibrinogenemia? * 1/1 Thrombin time APTT PT Immunologic fibrinogen level

    Immunologic fibrinogen level

  • 90

    Factor XII deficiency is associated with: * 0/1 Bleeding episodes Epistaxis Decreased risk of thrombosis Increased risk of thrombosis

    Increased risk of thrombosis

  • 91

    The most common subtype of classic von Willebrand’s disease is: * 0/1 Type 1 Type 2A Type 2B Type 3

    Type 1

  • 92

    Thrombin-thrombomodulin complex is necessary for activation of: * 1/1 Protein C Antithrombin Protein S Factors V and VIII

    Protein C

  • 93

    What clotting factors (cofactors) are inhibited by protein S? * 1/1 V and X Va and VIIIa VIII and IX VIII and X

    Va and VIIIa

  • 94

    Heparin-induced thrombocytopenia (HIT) results from: * 1/1 Antibodies to heparin Antibodies to platelets Antibodies to PF4 Antibodies to heparin-PF4 complex

    Antibodies to heparin-PF4 complex

  • 95

    In the Clauss fibrinogen assay the time for clot formation in plasma is measured after the addition of: * 1/1 Calcium Thrombin Phospholipids Fibrin

    Thrombin

  • 96

    A pregnant women has routine coagulation testing performed. PT and aPTT are normal. Her fibrinogen level is elevated at 450 (reference range 150-350) due to acute phase reactants during pregnancy. The other factor that may be elevated due to this is: * 0/1 FVII FVIII FXI FXIII

    FVIII

  • 97

    Platelet aggregation will occur with the end production of: * 1/1 Cyclooxygenase Arachidonic acid Prostacyclin Thromboxane A2

    Thromboxane A2

  • 98

    After the removal of red blood cells from the circulation hemoglobin is broken down into: * 1/1 Iron, porphyrin, and amino acids Iron, heme, and globin Heme, protoporphyrin, and amino acids Heme, hemosiderin, and globin

    Iron, heme, and globin

  • 99

    Deficiency of this enzyme is associated with a moderate to severe hemolytic anemia after the patient is exposed to certain drugs and characterized by red cell inclusions formed by denatured hemoglobin: * 1/1 Lactate dehydrogenase G6PD Pyruvate kinase Hexokinase

    G6PD

  • 100

    What protein is commonly defective in hereditary elliptocytosis? [BOC] * 1/1 Ankyrin Spectrin Band 4.1 Elliptocin

    Spectrin